Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hospital study tracks eye drop risks in 1,000 patients

NCT ID NCT07178600

Knowledge-focused Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will monitor 1,000 hospitalized patients who receive tropicamide/phenylephrine eye drops, commonly used to dilate pupils before eye surgery. Researchers will measure vital signs and ask about side effects at several time points after the drops are given. The goal is to identify which patients are more likely to have adverse reactions, such as high blood pressure or eye discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tropicamide/phenylephrine eye drops
What this could lead to
If successful, this could help doctors predict and prevent side effects from these common eye drops in hospitalized patients.
What could go wrong
This is an observational study, not a treatment trial. It only looks for patterns, so it won't directly improve care or test a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients over 18 years of age who have been hospitalized to undergo a surgical procedure at the "Instituto de Oftalmología Conde de Valenciana, IAP".

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who have authorized participation in the study by signing informed consent. * Patients over 18 years of age. * Any sex. * Patients from the "Instituto de Oftalmología Conde de Valenciana, IAP., sede Centro" who have been scheduled for a surgical procedure. * Patients for whom the administration of two drops of tropicamide/phenylephrine 8 mg/50 mg/mL is indicated. * Patients that presents any type of disease Exclusion Criteria: * Allergy to any component of the formulation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug effect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Drug-Related Side Effects and Adverse Reactions hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug effect Cardiovascular complication Hypertension Ocular discomfort Ophthalmology Phenylephrine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro

    RECRUITING

    Mexico City, Mexico Ciy, 06800, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.